News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Doctors don’t know what’s happening! New health app CAREFUL helps clinical teams reduce the dangers of handover

CAREFUL

Thousands of patients are dying every year and hospitals are wasting up to 15% of their entire budget as a result of poor handover. The UK NHS wastes at least £250m a year from delays to discharge, and the same problem is seen in hospitals throughout the world. Today, healthcare start-up CAREFUL has launched its platform to help make handover safe, save lives and speed-up patient flow in hospitals by making discharges quicker to save costs and improve care. Handover is a critical process in healthcare when responsibility for patients transfers from one clinician or team to another. In every hospital, thousands of such handovers take place every week. Most hospitals use a combination of inefficient, informal communication systems for handover including bits of paper, sticky notes, and WhatsApp messages. Established in 2021, Careful has been testing and building its tech platform to enable clinicians to seamlessly capture and update health data and records of patients in hospital care. CAREFUL is a digital health platform that enables visibility, accountability and collaboration as patients move through different care settings and interact with different care-givers. The platform provides hospitals, clinicians and multidisciplinary teams with a constantly updated, holistic view of every patient’s plan of care to ensure their safe and frictionless movement throughout their health journey. Research from CAREFUL* shows a quarter of all doctors and nurses worldwide use spreadsheets to record lists of patients and tasks. A clear view of the status of the hospital — and predicting future flows — is obscured. Staff don’t know what’s happening and nor do the patients. Even in digitally advanced hospitals, critical tasks are regularly lost or forgotten. “All these headaches can be solved quickly and easily with CAREFUL” says Dr DJ Hamblin-Brown, Founder & CEO of the company. “CAREFUL is a simple-to-use and easy-to-implement application which helps hospitals communicate internally, and also with patients and their families”. Dr Hamblin-Brown was motivated to build CAREFUL because his mother nearly died from a simple communication failure in a UK hospital. He adds, “Although clinicians take handover very seriously, errors still occur because staff are let down by the systems they are forced to use. With desperate shortages of clinical staff, hospitals need CAREFUL to help save money and save lives.” The WHO estimates that 15% of all hospital expenditure is wasted on adverse events that happen to patients – and that 80% of these are due to poor handover. This causes serious harm to patients, sometimes with fatal outcomes. Inadequate systems leave staff over-burdened and stressed, leading to resignations and burnout. Errors also cause delays. Beds are taken up by patients who should be discharged. Once at home, the problems continue. No one knows what the next steps are and patients are often lost to follow-up. Together this costs every hospital millions every year. Dr Johann Grunlingh, an NHS emergency medicine consultant and Intensive Care specialist in London. He and his team at Newham Hospital helped to test the application during development. He says, “Handover is a time consuming and dangerous process especially in critical care. CAREFUL fills a huge gap where Electronic Patient Record systems perform poorly. CAREFUL provides an action-focus that would benefit every care team in the NHS.” “CAREFUL can be up-and-running in any hospital, clinic, or care home in a matter of days”, says Dr Hamblin-Brown. It works on mobile, tablet or desktop presenting critical information for each patient, along with task lists assigned to individuals, clarifying who needs to do what, and when. As staff change shift, and patients move through the hospital, tasks and status information move with them – even out into the community or home. As a result, patients and staff know at all times what is happening, and who is responsible. Roohi Hamlani, CAREFUL’s co-founder and Head of Patient Participation is passionate about extending CAREFUL’s reach into care-homes and families, from whom patients receive the majority of their care. CAREFUL’s approach was based on her work in Asia improving outcomes with collaborative care for chronic disease patients. She says better workflows are about breaking-down silos. “To provide the very best care, clinicians, families and caregivers all need to work together across boundaries. CAREFUL bridges the gaps that exist today”. CAREFUL users can send, receive and share responsibility for patient care during peer-to-peer handover, internal referrals, discharges and transfers between organisations. Patient safety is improved because nothing is lost or forgotten. Patient information is added, reviewed and updated at every transition of care to ensure a complete and continuous health story across care settings. Caregivers contribute to the story as the patient moves between community care, hospital, teams and home or back into community care. Patients are invited to access and contribute to their own record. CAREFUL uses privacy-by-design principles and is regulatorily-compliant in UK, Europe, USA. As a cloud-based application, it is fully encrypted and protected. It is also fully interoperable using industry standard messaging – so that it can integrate with healthcare systems globally Dr Jeffrey Staples has led large hospital and health systems across Middle East and Asia building quality and operational excellence commented: “CAREFUL has global relevance across the private and public healthcare sectors. Hospitals find it hard to understand what is happening with patient flow in real time. Important data often stays in clinicians’ pockets or just gets thrown away. In my view, CAREFUL will significantly improve clinical and operational performance.” Recently, CAREFUL published the results of a study* on clinicians’ experience of handover. The findings were sobering. Errors in handover occur weekly or daily according to 12% of respondents. Nearly 10% had witnessed severe harm because of handover error. Dr Hamblin-Brown and Ms Hamlani are clear that “We work in an industry that is failing to take seriously the dangers of handover. It is arguably the most common, and one of the most important, processes. We harm both staff and patients if we fail to address the dangers of handover.” About CAREFUL CAREFUL is a digital health platform that enables visibility, accountability and collaboration as patients move through different care settings and interact with different care-givers. The platform provides hospitals, clinicians and multidisciplinary teams with a constantly updated, holistic view of every patient’s plan of care to ensure their safe and frictionless movement throughout their health journey. CAREFUL is backed by Artesian, The Pension SuperFund as well as Brinc and was recently welcomed into the Microsoft for Startups programme. The team is made up of experienced clinicians and technologists from every corner of the globe and are united by a shared goal: to ensure the right care is provided at the right time, by the right person, every time. Available on mobile, tablet and desktop, CAREFUL is designed to interoperate with and complement existing Hospital information systems/Electronic Patient Record systems and replace manual, paper-based systems or messaging apps with a future-focused collaboration tool. For more information please visit https://careful.online/ Contact Details Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://careful.online/

June 28, 2022 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

The Greeley Company Rebrands as Chartis Clinical Quality Solutions

Greeley

The Greeley Company, a division of The Chartis Group (Chartis) and a leader in clinical quality and patient safety services and solutions, will become Chartis Clinical Quality Solutions. Since Greeley joined Chartis three years ago, the two firms have worked closely to align their expertise and expand capabilities to support clients in achieving top-tier clinical performance. “Today is an exciting moment as our firm enters the next stage of growth by aligning our brand with Chartis,” said Greg Kopulos, President at Chartis Clinical Quality Solutions. “By leveraging Chartis’ performance improvement, care models, operations and change management expertise, we can expand the scope of how we support our clients exponentially. What won’t change is our absolute commitment to providing high-value services and solutions to our clients. I am looking forward to this next chapter.” Chartis Clinical Quality Solutions brings together the respective expertise and experience of both firms in four solution areas: High Reliability Care Solutions – Comprehensive offerings that align clinical quality and patient safety processes, operations, and structures to create high reliability organizations. Medical Staff Services Optimization – Enablement and optimization of organized medical staff services to improve efficiency, reduce administrative burden, and deliver the highest quality, most appropriate care. Education Solutions – Educational offerings that help physician and administrative leaders manage in a complex environment against challenges such as regulatory requirements, economic alignment, clinical quality, and burnout. Workforce Solutions – Expansion of Greeley’s interim staffing business to support clinical, business, and administrative leaders in addressing today’s complex workforce challenges. While much is changing, day-to-day operations and the Greeley Leadership team will remain the same. “Throughout the past three years, Chartis and The Greeley Company have worked together to introduce joint capabilities to clients,” said Ken Graboys, Co-Founder and CEO at The Chartis Group. “This rebrand is the culmination of incredible collaboration, and a shared commitment to healthcare organizations and the communities they serve. As Chartis Clinical Quality Solutions, we work with clients to materially improve patient quality, safety, and outcomes.” About Chartis Clinical Quality Solutions Chartis Clinical Quality Solutions is a partner to healthcare organizations nationwide, helping to advance patient safety and clinical quality for the past 30+ years. Through our four lines of business—High Reliability Care Solutions, Medical Staff Services Optimization, Education Solutions, and Chartis Workforce Solutions—we help healthcare providers achieve top-tier clinical performance. For more information, visit chartisquality.com. About The Chartis Group® The Chartis Group® (Chartis) is a leading healthcare advisory services firm serving healthcare providers, payers, service organizations, and investors. Different by design, Chartis brings an unparalleled breadth and depth of expertise in strategy, performance improvement, digital and technology, clinical quality and patient safety, health equity and belonging, and strategic communications. Learn how Chartis is helping to build a healthier world at chartis.com. Contact Details Brooke Ferreri +1 212-931-6182 bferreri@hotpaperlantern.com Company Website https://www.chartisquality.com/

June 27, 2022 01:45 PM Eastern Daylight Time

Article thumbnail News Release

Stupid Cancer and its partners release a statement regarding abortion access for cancer patients

Stupid Cancer, Inc.

The following joint statement was issued today by Stupid Cancer's Board of Directors and co-signed by Bright Spot Network, Cactus Cancer Society, Cervivor, Elephants and Tea, Escape, Family Reach, Fuck Cancer, Imerman Angels, Living Beyond Breast Cancer, Teen Cancer America, True North Treks, and The Ulman Foundation. Stupid Cancer and its Board of Directors is committed to the empowerment of people affected by adolescent and young adult (AYA) cancer. As patient advocacy organizations serving AYA patients, we join the medical community in fully renouncing any efforts to limit or remove access to safe abortion care. Abortion is a safe and essential healthcare right. Patients with cancer may face many difficult choices in their treatment journey. Patients who learn of a cancer diagnosis during pregnancy often must choose between continuing pregnancy (delaying essential life-saving treatments) and termination of pregnancy. Surgeries or medical treatment for cancer that could also result in loss of pregnancy would be considered abortion under certain state laws. This threatens the patient’s ability to receive cancer care in a timely fashion. Additionally, the continued interference of state legislatures into individuals’ personal healthcare decisions undermines the principles of the patient-physician relationship. These decisions are personal and should be made by patients in discussion with their medical team and not limited by legal consideration. Changes occurring in state laws ( Texas SB8, Oklahoma HB4327 ) and the recent ruling of the Supreme Court of the United States regarding Dobbs vs. Jackson Women’s Health Organization raise grave concerns regarding access to abortion care in this country. Multiple leading medical organizations including American College of Obstetrics and Gynecology (ACOG) 1, Society for Gynecologic Oncology (SGO) 2, American Society of Reproductive Medicine (ASRM) 3, North American Society of Pediatric and Adolescent Gynecology (NASPAG) and Society for Adolescent Health and Medicine (SAHM) have denounced the opinions of this ruling. Given trigger laws in effect in at least 25 states, swift and immediate loss of abortion access is expected. A joint statement from NASPAG/SAHM 4 outlines how these changes would affect adolescent and young adult (AYA) patients in particular. AYA patients undergoing cancer care often consider options for preserving their fertility prior to cancer therapies, including freezing embryos. Given the confusion and misconceptions that anti-abortion legislation has caused and more recent bans starting with fertilization, we also have grave concerns that these laws and those that follow will limit the ability of patients to access fertility preservation techniques and have control over reproductive decision making of their stored tissue in the future. Finally, given misconceptions about the mechanisms of actions of many of the most effective contraceptive methods (including emergency contraceptives), we have serious concerns about the potential for limitations on AYA patients' access to the best form of contraception for them. We, the undersigned, are patient advocacy nonprofit organizations supporting AYA patients and their loved ones. We remain committed to advocating for the AYA community to have resources to navigate treatment and survivorship on their own terms, inclusive of access to abortion care. Signed Stupid Cancer, Inc. Bright Spot Network Cactus Cancer Society Cervivor Elephants and Tea Escape Family Reach Fuck Cancer Imerman Angels Living Beyond Breast Cancer Teen Cancer America True North Treks The Ulman Foundation [1] American College of Obstetrics and Gynecology. (2022, May 2) ACOG Statement on Reports of a Draft Opinion in Dobbs v. Jackson [Press Release]. Retrieved from https://www.acog.org/news/news-releases/2022/05/acog-statement-on-reports-of-a-draft-opinion-in-dobbs-v-jackson [2] Society for Gynecologic Oncology. (2022, May 4) SGO Commits to Policy Action and Advocacy in Defense of Reproductive Rights. [Press Release]. Retrieved from https://www.sgo.org/news/sgo-commits-to-policy-action-and-advocacy-in-defense-of-reproductive-rights/ [3] American Society of Reproductive Medicine. (2022, May 3) ASRM Issues Statement Regarding Roe v. Wade and Its Possible Implications on Access to Reproductive Care. [Press Release} Retrieved from https://www.asrm.org/news-and-publications/news-and-research/press-releases-and-bulletins/asrm-issues-statement-regarding-roe-v.-wade-and-its-possible-implications-on-access-to-reproductive-care/ [4] North American Society of Pediatric and Adolescent Gynecology and Society for Adolescent Health and Medicine. (2022, May 17). SAHM/NASPAG Statement on Leaked Draft SCOTUS Opinion Regarding Mississippi v. Jackson Women’s Health Organization [Press Release]. Retrieved from https://naspag.memberclicks.net/assets/docs/SAHM%20NASPAG%20Statement%202022.05.17.pdf About Stupid Cancer: Stupid Cancer's mission is to help empower everyone in the adolescent and young adult (AYA) community by ending isolation and building community. Contact Details Stupid Cancer Alison Silberman +1 212-619-1040 media@stupidcancer.org Company Website https://stupidcancer.org/

June 27, 2022 01:36 PM Eastern Daylight Time

Article thumbnail News Release

New study reveals impact of hospital visitors on patient safety

Patient Safety Authority

Families, friends, and loved ones visiting patients in the hospital play an important role in improving patient safety, but there are times when their actions may be detrimental. A new report from the Patient Safety Authority reveals how visitor behaviors can influence the risk of patient harm. The study is highlighted in the June issue of PATIENT SAFETY. About 64% of the time, a visitor’s behavior had a positive impact on patient safety; 36% of the time it made patient safety worse. Harm occurred most frequently when visitors moved or physically stabilized a patient, provided or removed items such as food, or manipulated equipment. In contrast, visitor behavior was found to prevent patient falls, the administration of incorrect medication, and allergic reactions. The report also includes safety tips for visitors to the hospital. “It’s important that visitors do not help a patient walk, unless directed by a staff member,” says patient safety analyst Christine Sanchez who led the study. “What can visitors do to help? Alert staff about new or worsening symptoms, if they think a wrong medication is being given, or if something in a medical document doesn’t seem right. These are a few examples of actions that can help reduce harm.” Data for the analysis was drawn from PA-PSRS, one of the largest patient safety databases in the world, with more than 4 million event reports. Other topics in this issue of PATIENT SAFETY include: 2021 data reports from PA-PSRS - From the most common type of event in hospitals to healthcare-associated infections affecting nursing home residents, these concise analyses make the most complex information easy to understand. Pediatric dose calculation factors - Medication management is one of the most precarious processes when it comes to our youngest patients. A team from the MedStar Health Research Institute analyzed patient safety events and found that 81.6% of them might have been prevented with optimal technology. PATIENT SAFETY is the peer-reviewed journal of the Patient Safety Authority. A scientific publication, PATIENT SAFETY humanizes patient harm with stories, opinion pieces, and magazine-quality design. It has a readership of more than 45,000 people in 164 countries. About PSA Established under the Medical Care Availability and Reduction of Error (MCARE) Act of 2002, the PSA, an independent state agency, collects and analyzes patient safety data to improve safety outcomes and help prevent patient harm. http://patientsafety.pa.gov/ Contact Details Bev Volpe +1 609-230-4696 bev@madisongall.com Company Website http://patientsafety.pa.gov/

June 24, 2022 09:54 AM Eastern Daylight Time

Image
Article thumbnail News Release

CleverTap Recognized by Great Place to Work® Among India’s Great Mid-size Workplaces

CleverTap

CleverTap, the modern, integrated retention cloud, has been recognized by Great Place to Work® India as one of India’s Great Mid-size Workplaces 2022. CleverTap is recognized for creating and sustaining a high-trust, high performance work culture. In its 6th edition this year for India, the list has grown to include the top 75 companies, up from the top 50 until last year. The rigorous methodology to assess workplace culture and identify India's Great Mid-size Workplaces 2022 is considered the gold standard globally. In the Great Place to Work® India study, they have observed that the Great Mid-size Workplaces have gone above and beyond to create and sustain aspirational organizations. Effective leadership is visible in these workplaces that are fostering a culture of fairness and originality, while offering flexibility to their employees in the current hybrid work environment. Organizations that succeed in establishing high-trust, high-performance cultures, and maximizing human potential by bridging experience gaps, will be Great Places to Work For All in the future. “We’re very excited to be recognized by Great Place to Work® India as one of India’s Great Mid-size Workplaces. Even before the pandemic hit, we believed that an empathetic and flexible work culture is the essence of an organization’s growth,” says Sidharth Malik, Chief Executive Officer, CleverTap. “Our employees and their holistic well-being have always been the top priority for us. The recognition by Great Place to Work® India is a testament to our commitment of building a workplace that is inclusive and driven, and one that provides its people an environment to thrive and succeed in everything they do.” “With homes becoming an extension of people's workplaces, this year companies around the world were challenged to put their people at the center of their strategies. But the organizations that invested in their culture and people before the pandemic have overcome these challenges effortlessly. Being recognized as one of India’s Best Workplaces 2022 demonstrates these organizations' commitment to improving their culture and putting their people first, whatever challenges they face,” says Yeshasvini Ramaswamy, CEO, Great Place to Work®, India. As a global authority on workplace culture, Great Place to Work® has been studying employee experience and people practices across organizations for over three decades. Every year, more than 10,000 organizations from over 60 countries partner with Great Place to Work® Institute for assessment, benchmarking, and planning of actions to strengthen their workplace culture. About CleverTap CleverTap is the modern, integrated retention cloud that empowers digital consumer brands to increase customer retention and lifetime value. CleverTap drives contextual individualization with the help of a unified and deep data layer, AI/ML-powered insights, and automation enabling brands to offer hyper-personalized and delightful experiences to their customers. 1,200+ customers in 60+ countries and 10,000+ apps, including Gojek, ShopX, Canon, Mercedes Benz, Electronic Arts, TED, Jio, Premier League, TD Bank, Carousell, Papa John’s, and Tesco, trust CleverTap to achieve their retention and engagement goals, growing their long-term revenue. Backed by leading venture capital firms, including Sequoia, Tiger Global Management, and Accel, the company is headquartered in Mountain View, California, with offices in Mumbai, Singapore, Sofia, São Paulo, Bogota, Amsterdam, Jakarta, and Dubai. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap’s belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could amount in the actual result being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

June 24, 2022 03:18 AM Eastern Daylight Time

Article thumbnail News Release

NextFerm Technologies announces its first commercial delivery of ProteVin™, in the U.S

NextFerm Technologies Ltd.

Company has delivered two tons of raw material to SpaceMilk, a health and wellness brand, expected to launch its ProteVin™ based product during this summer The company marks the achievement of the second strategic milestone (out of five) for 2022. This announcement follows an earlier announcement made this week about initiating ProteVin’s commercial production The Company is expected to continue supplying ProteVin to customers in the coming weeks, and is currently in dialogues with leading food and dietary supplement brands, for the integration of ProteVin™ in their alternative products (Yokneam Illit, June 22, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today of the first commercial delivery of ProteVin to a U.S customer. The Company delivered 2 tons out of SpaceMilk’s purchase order obtained in July 2021. SpaceMilk (Former PrimaLife Nutrition), is a US health and wellness brand and the first to launch a vegan protein powder based on ProteVin™. This protein powder will enable consumers to enjoy vegan protein with animal like nutritional value and perfect taste. The ProteVin™ brand name will appear on the product label, as the leading nutritional substance in the product. SpaceMilk is expected to be launched and available for sale to end users during the coming summer months, mostly online. The supply of the remaining of the order, as well as other open orders, shall continue during the coming weeks. The delivery of the first purchase order marks the achievement of the second out of five milestones set by the Company for 2022. This announcement follows an earlier announcement made this week about the initiation of commercial production (first milestone). The Company continues to progress towards the completion of its objectives for 2022, which include: increasing market demands, receiving additional purchase orders for ProteVin™ and increasing commercial production capacity from current scale of tens of tons to a scale of hundreds of tons per year in 2023. Boaz Noy, Chief Executive Officer of NextFerm, said: "We are excited to launch ProteVin, our vegan protein, as planned, and supply it to our first customers, who has expressed confidence in the product by placing purchase orders even before production has started. The alternative protein market, is currently estimated at $20 billion, and is expected to grow to about $290 billion by 2035, at an annual growth rate of above 20%. Today, it is indisputable that it is the main growth engine for the global food industry. This growing trend of consuming vegan foods as part of a balanced diet is becoming ever more popular within the general population that considers these foods to be healthier and more sustainable. "We are proud to be one of the leading innovators in the alternative protein B2B market, by offering the only vegan protein with a neutral flavor and animal like nutritional value that allow it to be incorporated into a variety of foods. We are also making progress in meeting the rest of the milestones for 2022, including: dialogues with food and nutrition brands, who are looking into incorporating ProteVin into their alternative product lines in such fields as dairy substitutes, powder premixes, snacks and more. At the same time, we are preparing to increase production capacity to a scale of hundreds of tons per year, in order to respond to the expected increase in demands." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

June 22, 2022 09:50 AM Eastern Daylight Time

Article thumbnail News Release

SC Johnson and Global Fund Launch Partnership to Eradicate Malaria; Urge World Leaders to Boost Action to End One of the World’s Deadliest Diseases

SC Johnson

SC Johnson has teamed up with the Global Fund to accelerate the elimination of malaria, a deadly yet preventable and treatable disease that claims the life of a child under the age of five every minute. In addition to announcing their partnership, the two organizations are calling on leaders attending the 2022 Commonwealth Heads of Government Meeting (CHOGM) in Kigali to redouble their efforts to help eliminate the disease. Under an agreement signed by Peter Sands, Executive Director of the Global Fund, and Fisk Johnson, Chairman and CEO of SC Johnson, the partnership will leverage SC Johnson’s core competencies in entomology to drive measurable and economically sustainable social impact in the malaria space in Burundi, Democratic Republic of Congo, Kenya, Rwanda, South Sudan, Tanzania, Uganda and Zanzibar. “Malaria claims the lives of hundreds of thousands of children every year, and yet it remains one of the most neglected diseases on the planet,” said Fisk. “We’ve been working for decades on preventative interventions and innovative solutions, such as spatial repellents, to help those most at risk. We know we can’t tackle this insidious disease alone. That’s why we are partnering with the Global Fund and calling on leaders here in Kigali to redouble their efforts to help end malaria once and for all.” For more than 60 years, SC Johnson has studied insects and the diseases they carry at the company’s Center for Insect Science and Family Health, one of the world’s largest privately funded urban entomology centers. SC Johnson has leveraged that knowledge and expertise to help protect families from insect-borne diseases like malaria and dengue. As part of this partnership, SC Johnson will be providing technical knowledge to support country-led efforts to eliminate malaria. “SC Johnson’s strong expertise in entomology can be a key asset in supporting our partners to accelerate progress in the fight against malaria,” said Peter. “This new initiative is a great example of how the private sector can bring innovative solutions and technical expertise to bear on the fight against the world’s deadliest diseases. Ahead of the Global Fund’s Seventh Replenishment, we will continue to count on our private sector partners to invest with us to defeat HIV, TB and malaria, end health inequity and protect humanity from pandemics.” The Global Fund provides 56% of all international financing for malaria programs (39% of total available resources) and has invested more than US$16 billion in malaria control programs to date. In countries where the Global Fund invests, malaria deaths have dropped by 26% between 2002 and 2020. The announcement comes ahead of the Global Fund’s Seventh Replenishment Conference hosted by U.S. President Joe Biden later this year. The Global Fund’s target is to raise at least US$18 billion to fund its next three-year cycle of grants. A successful Replenishment would save 20 million lives, cut the death rate from HIV, tuberculosis and malaria by 64%, and strengthen systems for health to build a healthier, more equitable world. In the fight against malaria, a successful Replenishment would cut malaria deaths by 62%, reduce malaria cases by 66% and eliminate malaria from an additional six countries by 2026. About the Global Fund The Global Fund is a worldwide movement to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US$4 billion a year to fight the deadliest infectious diseases, challenge the injustice which fuels them and strengthen health systems in more than 100 of the hardest hit countries. Since the beginning of the COVID-19 pandemic, we have invested an additional US$4.3 billion to fight the new pandemic and reinforce systems for health. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund has saved 44 million lives. Information on the work of the Global Fund is available at www.theglobalfund.org Follow the Global Fund on Twitter: http://twitter.com/globalfund Join the Global Fund on Facebook: http://www.facebook.com/theglobalfund About SC Johnson Founded in 1886 and headquartered in Racine, Wisconsin USA, SC Johnson believes that a more sustainable, healthier and transparent world that inspires people and creates opportunities isn't just possible – it’s our responsibility. A heritage of innovation and bold, transparent decisions is why our high-quality products and iconic brands – including OFF! ®, Raid ®, Glade ®, Windex ®, Scrubbing Bubbles ®, Ziploc ®, Mrs. Meyer’s Clean Day ®, method ®, Autan ®, Baygon ®, Mr Muscle ®, Duck ®, Lysoform ® and more – are in homes, schools and businesses in virtually every country worldwide. As a global, purpose-led company, we are committed to making the world a better place today and for future generations. That means relentlessly bringing our expertise in science, innovation and partnerships to bear on some of the world's most pressing environmental and health issues like reducing plastic waste and eradicating malaria. Around the world, we use our resources to unlock greater economic and educational opportunities for people and communities where access may be limited, but curiosity and potential are limitless. See how SC Johnson is a Family Company At Work For a Better World by visiting scjohnson.com or joining us on Facebook, Twitter, LinkedIn, Instagram and YouTube. Contact Details SC Johnson Jen Erickson +1 262-598-6726 jericks@scj.com Company Website https://www.scjohnson.com/

June 22, 2022 03:00 AM Eastern Daylight Time

Article thumbnail News Release

First-of-Its-Kind National Canine Cancer Registry Offers Ray of Hope to Dog Lovers

YourUpdateTV

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop a tumor, and almost 50% of dogs over age 10 will develop cancer. Recently, Dr. Susan Ettinger, “Dr Sue Cancer Vet”, Veterinary Cancer Specialist and Take C.H.A.R.G.E. Scientific Advisory Board Member, and Lisa Conte, Jaguar Health Founder & CEO, conducted a satellite media tour to talk about the first-of-its-kind national canine cancer registry that offers a ray of hope to dog-lovers everywhere. A video accompanying this announcement is available at: https://youtu.be/UaYbeRw7JGY Designed to be interactive and with open access to academia, the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. ( C anine H ealth A nd R e G istry E xchange), co-sponsored by Jaguar Animal Health, TogoRun, and Ivee, is a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index that provides the veterinary community and canine pet owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions, at no cost. The Registry began with a retrospective review of more than 35,000 anonymous canine patient records uploaded into a secure customized database and more than 830 confirmed cancer diagnoses and is interactive. Protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location Powered by animal health software company Ivee (Intelligent Veterinary Enhanced Experience), only information from canine patients that have been diagnosed with cancer is accessed and data is continuously protected. All research and academia related activities are de-identified and anonymized, following all General Data Protection Regulation (GDPR) guidelines, to ensure 100% participant and veterinary information protection. Currently there is no published state-by-state registry in the U.S. documenting canine cancer, while there are multiple regional European registries that exist and serve to inform both the veterinary and human oncology communities. The Registry also includes the first nationwide Gallup survey of pet owners addressing their experience with canine cancer. Canine Cancer Impact on Humans - Dealing with canine cancer has a major impact on dog owners’ well-being, including depression, anxiety, lack of sleep, and missing work or other obligations; for example, 63 percent of respondents reported feeling a lot of stress and 58 percent reported feeling down and depressed a lot during their dog's cancer. And, more than 8 in 10 dog owners favor the creation of a canine cancer registry to better understand the disease and advance treatments The survey found that the incidence – the percent of U.S. dogs newly diagnosed with cancer in 2021 – was approximately five times incidence of newly diagnosed cancer in humans that year, which is startling since researchers have assumed that canine cancer rates mirror human cancer rates. A complementary Index was established based on pet owner responses to this multi-year nationwide Gallup survey assessing pet owner experience with their dog’s cancer diagnosis and treatment. Together the Registry and Index provides the veterinary community with important information to guide canine cancer diagnosis and treatment decisions and support dog owners by improving canine cancer care. The Gallup survey closed on March 30, 2022, with over 3,800 respondents, including over 600 responses from dog owners with canine cancer experience. Canine cancer patient records uploaded to the Registry are updated regularly thanks to ongoing input from participating veterinarians and owners of dogs who have been diagnosed with cancer. If your dog passed away from cancer, you can contribute to building hope for all dog lovers by uploading your canine pet’s medical records as well. How to get involved as a veterinarian: · If you are a veterinarian and interested in having your clinic/practice opt into the Take C.H.A.R.G.E. Registry, please visit TakeChargeRegistry.com to fill out the Veterinarian Practice Registration form. · All research and academia related activities will be de-identified and anonymized to ensure 100% participant and veterinary information protection. · Once you opt in, the Take C.H.A.R.G.E. Registry will have access to all of your current and newly diagnosed canine patients with cancer. These files will be automatically uploaded into the Take C.H.A.R.G.E. Registry in real time, so no further action is needed once you opt in. How to get involved as a dog owner: · If you are a pet owner and have a PDF of your dog's medical records, simply upload them into the Registry by visiting TakeChargeRegistry.com. · If you do not have your dog's medical records, tell your veterinarian about the Registry at your next visit and encourage them to join! · Follow us on our social channels and reshare with your friends! @Take C.H.A.R.G.E. @takechargereg @takechargeregistry --------------------------- About Susan Ettinger Dr. Sue Ettinger is a practicing veterinary cancer specialist, international speaker, book author, and vlogger (video blogger). She is one of approximately 450 board-certified specialists in medical oncology in North America and currently practices at Veterinary Referral and Emergency Center in Norwalk, Connecticut. She is co-founder and Chief Medical Officer of Fidu, a teleconsulting company to bring together general practice veterinarians and boarded veterinary specialists. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003. She was voted the 2019 Western Veterinary Conference (WVC) Small Animal Continuing Educator of the Year and has recently received awards for Exceptional Doctor Performance and the Public Relations Achievement. Also known as Dr Sue Cancer Vet®, Dr. Sue is the co-author of the Second Edition of The Dog Cancer Survival Guide, which is a best-selling book in small animal health for the last several years. She is a frequent contributor to many veterinary publications, including Today’s Veterinary Practice, Today’s Veterinary Business, Clinician’s Brief, Veterinary Team Brief, & DVM360. She also has co-hosted the podcast The Pet Cancer Vet and is a frequent guest on many veterinary podcasts. There are many myths and misconceptions about cancer in dogs and cats. Most cancers are treatable, and there are a variety of treatment options. Dr Sue’s focus is to provide comprehensive and compassionate care. She strives to minimize side effects – from the cancer itself and treatment – to help her patients lead active, normal lives even while undergoing treatment. Her motto is live longer, live well. Dr. Sue is most passionate about raising cancer awareness, and she has developed “ See Something, Do Something, Why Wait? Aspirate.® ” to promote early cancer detection and diagnosis. This cancer awareness initiative for skin and superficial tumors in dogs and cats provides a set of guidelines for pet owners and veterinarians to help identify the best management for skin and subcutaneous (under the skin) masses in dogs and cats. Masses must be sampled and evaluated under a microscope to determine what they are. The sooner we determine whether a mass is cancerous and should be removed, the better for our pets. Most skin and subcutaneous tumors can be cured with surgery alone if diagnosed early when masses are small. Early detection saves lives. Lisa Conte, Jaguar Health Founder & CEO Lisa Conte is the founder, president and chief executive officer, and a member of the board of directors of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs. Mytesi®, the company’s FDA-approved drug product, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance. In 1989, Ms. Conte also founded Shaman Pharmaceuticals, Inc. and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including a recent Entheogen Therapeutics Initiative looking at psychoactive plants for novel cures for mental health disorders; and Napo Therapeutics, S.p.A., a company established in Italy with a focus on the treatment of rare diseases from plant-based prescription medicines under license from Jaguar Health. Ms. Conte is currently a member of the board of directors of the Healing Forest Conservatory and Napo Therapeutics, and serves on the Editorial Advisory Board of Life Science Leader magazine. She holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College, and is also the parent of two Jack Russell Terriers and a Belgium Warmblood. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 21, 2022 05:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

NextFerm Technologies Announces First Commercial Production of ProteVin™, Its Vegan Protein

NextFerm Technologies Ltd.

This marks the achievement of first out of five strategic milestones set by the company for 2022 The Company expects to supply first orders of ProteVin™ in the coming weeks; Company is currently in dialogues with food and dietary supplement global companies for the integration of ProteVin™ in their alternative product lines NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced the end of commissioning period of the commercial facility in Canada and first commercial production of ProteVin™, Its Vegan Protein. The operation of first commercial facility following commissioning and successful production of first batches mark the achievement of the first milestone out of five milestones set by the company for 2022. The Company continues to progress towards achieving the rest of its objectives for 2022, including delivery of initial orders received, increasing market demand for ProteVin™, receipt of additional purchase orders and expanding penetration into the global food market. In parallel, increasing commercial production capacity to an industrial scale of hundreds of tons per year in 2023. Boaz Noy, Chief Executive Officer of NextFerm, said: "Initiating commercial production of Protevin™, marks a significant milestone for the company moving forward from R&D phase to commercial phase. Achieving this milestone allows us to progress towards achieving the additional milestones we set for 2022. In the coming weeks, we expect to supply first orders of ProteVin™ for customers in the field of sports nutrition formulas." "The alternative protein market is the main growth engine of the global food industry, and we expect high demands for Protevin™, as a proprietary vegan protein source for a variety of alternative food products, with a rich amino acid composition similar to animal-based protein, highest digestibility factor (PDCAST=1) and neutral flavor." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE: NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm has just commercialized the product as reported. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

June 20, 2022 10:05 AM Eastern Daylight Time

1 ... 212213214215216 ... 300